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Abstract
Background: Human infection studies (HIS) are valuable in vaccine development. Deliberate infection, however,
creates challenging questions, particularly in low and middle-income countries (LMICs) where HIS are new and
ethical challenges may be heightened. Consultation with stakeholders is needed to support contextually
appropriate and acceptable study design. We examined stakeholder perceptions about the acceptability and ethics
of HIS in Malawi, to inform decisions about planned pneumococcal challenge research and wider understanding of
HIS ethics in LMICs.
Methods: We conducted 6 deliberative focus groups and 15 follow-up interviews with research staff, medical
students, and community representatives from rural and urban Blantyre. We also conducted 5 key informant
interviews with clinicians, ethics committee members, and district health government officials.
Results: Stakeholders perceived HIS research to have potential population health benefits, but they also had
concerns, particularly related to the safety of volunteers and negative community reactions. Acceptability depended
on a range of conditions related to procedures for voluntary and informed consent, inclusion criteria, medical care
or support, compensation, regulation, and robust community engagement. These conditions largely mirror those in
existing guidelines for HIS and biomedical research in LMICs. Stakeholder perceptions pointed to potential tensions,
for example, balancing equity, safety, and relevance in inclusion criteria.
Conclusions: Our findings suggest HIS research could be acceptable in Malawi, provided certain conditions are in
place. Ongoing assessment of participant experiences and stakeholder perceptions will be required to strengthen
HIS research during development and roll-out.
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Background
Human Infection Studies (HIS), sometimes referred to
as human challenge studies, involve deliberately infecting
healthy adult volunteers with a microbial pathogen, such
as malaria parasites or typhoid bacteria. HIS are often
used for vaccine testing, with volunteers vaccinated be-
fore infection to test potential vaccine candidates. HIS
can be conducted much more rapidly and with far
smaller sample populations than standard efficacy trials,
which means HIS can accelerate vaccine development
[1, 2]. HIS science has contributed to new vaccines in
several areas, including typhoid and malaria [2–4]. While
HIS have been conducted for decades in High-Income
Countries (HICs), they are much newer in Low and
Middle-Income Countries (LMICs) [2, 3]. The highest
burdens of vaccine-preventable disease are found in
LMICs, and different biological and environmental con-
ditions, including population genetics and pathogen
strains, mean findings from vaccine trials in high-
income settings do not always apply [5]. Consequently,
conducting HIS in LMICs holds the potential to help
develop effective vaccines for these populations.
The deliberate infection involved in HIS science
creates challenging questions for ethical practice and
community engagement [6, 7]. Challenges are particu-
larly apparent in LMICs. For example, informed consent
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and fair compensation are complex in contexts of lim-
ited research experience and high poverty; health sys-
tems may lack adequate facilities to monitor and treat
adverse events, and regulatory guidelines may be limited
[2, 4, 8–10]. The growing literature on HIS ethics sug-
gests a range of ethical principles, including a strongly
justified research question that can only be answered
through HIS, independent review, qualified and experi-
enced researchers, rigorous informed consent, safe selection
of participants, minimisation of risks and no irreversible
harm, protection of contacts and the environment, com-
pensation that avoids undue influence, compensation for
harm, and public involvement [4, 6, 8]. However, further
evidence is needed to guide researchers and ethics commit-
tees on appropriate frameworks for HIS, particularly in
LMICs [10, 11].
Stakeholder consultation to generate evidence on effect-
ive and acceptable approaches can help to inform ethical
guidance and immediate HIS study design [2, 8, 12]. Such
consultation can provide insight for critical decisions such
as inclusion criteria, recruitment, informed consent, and
comprehension testing, residential stays, compensation,
withdrawals, and community engagement [4, 13].
Undertaking HIS in Malawi
The Malawi-Liverpool-Wellcome Trust Clinical Research
Programme (MLW) is planning Streptococcus pneumoniae
HIS in Malawi (the Malawi Accelerated Research in Vac-
cines using Experimental and Laboratory Systems project,
or (MARVELS)) [14]. This project builds on over a decade
of pneumococcal HIS research at the Liverpool School of
Tropical Medicine (LSTM), UK, and is predicated on the
need for new pneumococcal vaccine in Malawi as current
vaccines do not create herd immunity [15]. Streptococcus
pneumoniae (pneumococcus) is a bacterial pathogen com-
monly found carried in the nose. If the pneumococcus
spreads to the lungs, blood, or brain, it causes serious
infection, including pneumococcal pneumonia, sepsis, and
meningitis, respectively [16, 17]. In Malawi, pneumococ-
cus is found in 90% of all children’s noses and 40% of
adults with Human Immunodeficiency Virus (HIV) (10–
20% adults without HIV) [15, 18, 19]. The project con-
ceives a series of HIS, starting by establishing the feasibil-
ity of carriage in 12–36 participants. If effective, the
project would move to further stages of vaccine testing,
scaling up to around 150–400 participants per study de-
pending on the stage and study focus. Volunteers would
be exposed to pneumococcus through a saline solution
dropped into the nose, and closely monitored for safety.
Given uncertainties around participant contact and
hospital access, a three-day residential stay is planned for
volunteers following inoculation. The provided accommo-
dation to participants is located in close proximity to one
of Blantyre’s large private hospitals.
To reflect on the implications of undertaking HIS in
Malawi, MLW and partners organised a workshop on the
potential and challenges of HIS in Malawi in 2017. This
workshop brought together government stakeholders,
ethics committee members, and researchers, including
people with experience of conducting and regulating HIS
elsewhere in Africa and in HIC [2]. The workshop identi-
fied a need for community consultation to understand the
acceptability and ethics of HIS in the Malawi context. This
study responds to this recommendation.
Aims of this study
Our immediate aim in conducting the research reported
in this paper was to generate evidence on stakeholder
perceptions and preferences that could inform MLW’s
decisions about whether to proceed with HIS in Malawi
and, if so, on MARVELS design and implementation.
While the MARVELS team felt HIS had considerable po-
tential for benefit in Malawi, a decision to apply for permis-
sion to conduct a feasibility study depended on knowing
whether or not HIS would be welcome and socially appro-
priate. Approvals for pneumococcal HIS feasibility are still
pending. The data presented in this paper were included in
the ethics submission to support their review. We also
aimed to support the wider development of ethical frame-
works for HIS science in Malawi and other LMICs through
information on stakeholder perceptions of ethical chal-
lenges and potential approaches in this context.
In considering the acceptability of HIS, we were inter-
ested in a definition of acceptability that involves more
than tolerance [20]. MLW’s aim is that communities and
other stakeholders should feel highly positive about HIS
research in Malawi, seeing HIS as relevant and ethical,
rather than just allowing HIS to take place. We wanted
to find out whether pneumococcal HIS would be seen as
worthwhile and ethical and how HIS could be designed
to ensure it met stakeholder standards, expectations, and
the highest ethical standards.
Methods
We used Focus Group Discussions (FGDs) and individ-
ual interviews to examine stakeholders’ perceptions and
opinions on the acceptability and ethics of HIS research
in Malawi.
We conducted 6 deliberative FGDs [21] with MLW
frontline research staff, medical students, and three
sets of community representatives: chiefs (local com-
munity leaders), religious leaders, and members of
MLW’s Community Advisory Group (CAGs). Front-
line research staff included research nurses and field-
workers, and we focused on staff involved in vaccine
and other clinical trials that involved some procedures
that would be used in pneumococcal HIS (e.g., nasal
samples, health screening, and in-patient stays). The
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CAGs comprise representatives of active community-
based organisations located in rural or urban Blantyre.
CAG members were elected by their communities,
and their main role is to advise MLW on appropriate
engagement with communities for research. The
chiefs and religious leaders involved in this study had
no previous official engagement with MLW but were
aware of MLW’s existence. In addition, some of these
community leaders had previously participated in re-
search conducted by other research institutions.
To allow participants to reflect and share considered
perspectives, we conducted Follow-Up Interview (Fup)
after 2–3 weeks with 3 participants from each FGD to
identify any change in views or further reflections. We
selected participants for follow-up interviews based on
the opinions contributed in FGDs and level of partici-
pation, focusing on those who had expressed particu-
larly critical or cautious views that we wanted to
explore further, those expressing their views most
strongly, and participants who had spoken little dur-
ing group discussions. This strategy proved useful for
ensuring we did not misinterpret original strong opin-
ions and gathered views from those less confident to
speak in a group setting.
We also conducted 5 Key Informant Interviews
(KII) with a combination of Research Ethics Commit-
tee (REC) members, senior clinicians at the hospital
where pneumococcal HIS (MARVELS) would take
place, and district health management officials. The
sample of participants is shown in Table 1. In later
FGDs and interviews, no new issues emerged, so we
concluded that data saturation had been reached and
ended data collection [22].
Data collection procedures
Interviews and focus groups used a semi-structured topic
guide (Additional file 1) with open-ended questions about
views on HIS, including perceived benefits and concerns,
particular procedures (such as inclusion criteria, compensa-
tion, and safety measures), the types of HIS that would be
acceptable in Malawi and the overall ethics of HIS. As HIS
research had not yet been conducted in Malawi, we antici-
pated that few, if any, FGD and interview participants
would have heard of HIS or be familiar with HIS proce-
dures. To ensure participants could give views based on
some understanding of HIS, we provided information on
HIS during each FGD and interview and encouraged partic-
ipants to ask questions if they wanted more information.
This approach drew on ideas of deliberate discussion, used
in empirical ethics research to uncover participants’ in-
formed, considered, and collective views on a normative
question [23]. Information on the general HIS approach
was provided at the start, and more specific information
about the potential MARVELS plan and pneumococcal
HIS was provided later once participants had given initial
views. In addition, further information was provided as
needed in response to questions from participants or where
we noticed misconceptions about procedures that would be
involved (e.g., that children would be enrolled, that the resi-
dential stay would involve quarantine, or that HIS would
help the development of treatment rather than vaccine).
We were conscious that the views expressed by stake-
holders would be heavily influenced by the information
we provided. We wanted to avoid describing HIS in a way
that only emphasised benefits and discouraged any critical
views, but we were also cautious about creating fear and
rumours based on misunderstandings (e.g., if we did not
Table 1 Stakeholders for FGDs, follow up interviews and key informant interviews
Method Stakeholder group Number of participants
Focus group discussion Frontline researcher staff (research
nurses and fieldworkers)
9 (2 FGDs, one with 4 and one with
5 participants) (9 females, 1 male)
Community Advisory Group (CAG)
members (Blantyre urban)
10 (5 females)
Chiefs (Blantyre rural) 10 (4 females)
Religious leaders (Blantyre urban) 10 (1 female)
Medical students 10 (4 females)
Post-FGD follow-up interviews with
a sample of FGD participants
Frontline researcher staff 3 (All females)
CAG members 3 (2 females)
Chiefs 3 (2 females)
Religious leaders 3 (1 female)
Medical students 3 (1 female)
In-depth interview Research ethics committee (REC) members 2
Senior clinicians 2
District health management officials 1
Total 69 (33 females)
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discuss planned procedures for safety). To balance this,
we sought to present information neutrally and to focus
on procedures that would be involved in HIS and docu-
mented experience in relation to safety (e.g., plans for a
residential stay, and the number of severe adverse events
recorded in LSTM). The information provided was devel-
oped through discussion among the study team. To en-
courage openness and reduce courtesy bias, we
highlighted that there are different views about whether
HIS is acceptable, that there was uncertainty about appro-
priate procedures, and that the MLW team needed stake-
holder feedback and guidance. We also emphasised that
the social scientists primarily responsible for conducting
the interviews and FGDs were not part of the main MAR-
VELS team. One of the MARVELS scientists who had
worked on HIS in LSTM (KJ or JR) was involved in part
of 4 FGDs to explain the detailed MARVELS procedures
and answer questions from participants. We were con-
scious that their involvement might increase courtesy bias
but decided it was important to explain additional details
for participants and found that participants appreciated
the opportunity to ask questions directly of people who
had been involved in HIS in the UK. For FGDs where
these scientists were involved, we allowed time, after they
had left for further discussion, in case participants, were
more reluctant to share critical views with the HIS scien-
tists present. Follow-up interviews provided a further op-
portunity for participants to share any views they may
have been reluctant to express in front of those involved
more directly in HIS. This combination of deliberative
FGDs and follow-up interviews has been effective for simi-
lar ethical topics in similar contexts [24].
FGDs with community representatives were conducted
at a neutral venue, while follow-up interviews were held
at places chosen by participants (their homes or work-
places). For MLW staff and medical students, FGDs and
follow-up interviews took place at the MLW office in
Blantyre, as the MLW setting is more familiar for these
groups and so less likely to discourage open discussion.
All KIIs took place at participants’ workplaces.
Data processing and analysis
All FGDs and interviews were audio-recorded and tran-
scribed, and those conducted in Chichewa were trans-
lated into English.
The analysis was ongoing during fieldwork, using an it-
erative approach to identify emerging themes that could be
clarified or explored further through later data collection.
We conducted thematic coding in NVivo using broad de-
ductively defined themes (such as views on inclusion cri-
teria or perceived benefits of HIS) and inductively derived
sub-themes (such as impacts on household members or
population benefit). We also used framework matrices to
compare perspectives between different stakeholders. Two
researchers (KG and BK) worked together on coding to
compare interpretations and agree on a coding framework.
Ethical approval
The study received ethical approval from the Liverpool
School of Tropical Medicine and Malawi College of
Medicine Research Ethics Committee. We sought per-
mission from Principal Investigators at MLW and the
College of Medicine to speak to frontline research staff
and medical students, respectively. All participants re-
ceived written information sheets and verbal explana-
tions and gave written consent.
Results
In this section, we present our findings under three
broad headings. First, we describe stakeholders’ views on
the acceptability of pneumococcal HIS, including per-
ceived benefits, concerns, and views about whether over-
all pneumococcal HIS might be acceptable and ethical in
Malawi. Second, we report stakeholders’ suggestions on
the requirements for pneumococcal HIS to be accept-
able, including appropriate models of consent, a fair se-
lection of research participants, and the availability of
medical support. Third, we describe views on HIS for
other diseases beyond pneumococcus, to consider the
acceptability of HIS that require different procedures.
Views on the acceptability of pneumococcal HIS research
in Malawi
Perceived benefits of HIS
All stakeholder groups saw potential benefits of pneumo-
coccal HIS research in Malawi, centred on the potential to
improve population health. Within this, key issues in-
cluded the high burden of pneumococcal disease and the
value for a vaccine suited to the Malawi population.
In relation to pneumococcal disease, almost all stake-
holders focused on pneumonia rather than other types of
pneumococcal disease (only medical students mentioned
sepsis). Stakeholders noted the high incidence and severity
of pneumonia disease and suggested that developing a
vaccine would protect people from ill-health.
“I think it is welcome because pneumonia takes a
lot of lives […] a vaccine to prevent pneumonia is
really needed.” (Religious Leader, FGD6)
A vaccine developed specifically for the Malawi context
was considered valuable given differences in genetic
background and environmental context.
“It’s indeed right to conduct the research […] the
drugs we have here were developed in Europe and
maybe because of differences in climate and our
bodies; those drugs don’t work here” (Chief, FGD4)
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“These studies have been done in a setting like the
UK, but it’s different from here, isn’t it? Here there is a
number of things such as genetic and environmental
factors that may have a bearing on how people
respond to pathogens” (Senior clinician, KII)
While many stakeholders mentioned these benefits,
some raised questions about the potential value of HIS
research. In particular, while community participants
seemed confident that HIS would deliver solutions for
population health, a few key informants expressed un-
certainty about the likely impact of pneumococcal HIS,
perhaps reflecting awareness of both the unpredictability
of research and the need to prioritise among competing
research agendas.
“I am just interested to know why you want to do a
HIS study on pneumococcus now in Malawi. We
know that yes, Streptococcus pneumoniae is a big
problem, […], so what’s changed for this to come up
now? […] what will be its impact?” (Senior clinician,
KII)
Perceived concerns about HIS
While stakeholders saw HIS as having potential benefits,
they also had concerns. Key issues emphasised by all
stakeholder groups were safety and community reactions.
Participant safety On safety, the deliberate infection
was initially perceived as carrying significant risks by
many stakeholders. However, when we explained the
focus on pneumococcal carriage (that is, only observing
ability of the bacteria to live in the nose rather than
causing pneumonia or other pneumococcal diseases),
the prevalence of carriage and that there is low rate of
adverse events in similar HIS in the UK, many stake-
holders were reassured about safety.
“If you are just monitoring whether someone has it
in their nose without it necessarily affecting that
person, then you aren’t causing any harm for people
to be scared” (Religious leader, FGD6-Fup)
“I don’t think it will have any risks and I don't think
it’s as intense as I thought before […] with how you
have explained that you’re just looking at carriage, I
think it’s safer” (Frontline research staff, FGD1-Fup)
Nevertheless, safety concerns remained among some
stakeholders, particularly those involved in medical care
and research. Key issues were the unpredictability of in-
dividual biological reactions to the pneumococcus and
limited healthcare facilities to manage severe adverse
events in Malawi.
“People react differently to those agents, maybe be-
cause of their difference in biology, so just in case
someone experiences the infection, and dies, […] so
as researchers, how prepared are you to handle
such…?” (Medical student, FGD5-Fup)
“Obviously you would want to do it in a setting
whereby if a participant is sick, you are able to give
all the treatment that is necessary, such as High De-
pendency Unit care or Intensive Care Unit. But in
Malawi it’s a bit tricky because we already struggle
with resources to take care of patients that are very
sick.” (Senior clinician, KII)
Even when participants felt procedures were largely
safe, some were concerned about the psychological im-
pact of participation in HIS related to fear of infection.
“That psychological part of knowing for sure I have
been infected - I think they could not interact nor-
mally or be as productive as they could, because
they would have that psychological mind-set that ‘I
may be sick, let me restrict myself’.” (District Health
Management, KII)
Negative community reactions Partly linked to this
concern about fear, all stakeholder groups expressed
concern about negative community reactions to HIS, be-
lieving communities would see HIS research as high-risk
and that misconceptions and rumours were likely. For
example, participants mentioned the potential for ru-
mours about the purpose of deliberate infection, links
to witchcraft, and the intentions of non-Malawian re-
searchers, particularly because MLW may be seen as
a foreign institution.
This concern about community reactions partly reflected
the context of recent rumours around ‘bloodsucking’ in
Malawi: in 2017, there were widespread rumours about
bloodsuckers, with related community violence and some
disruption to community-based research [25, 26]. This
recent experience heightened sensitivity to potential
community distrust:
“There are concerns, people don’t trust their fellow
humans. [or] believe that an organisation has come to
help, for example, the issue of bloodsuckers. So to just
enter a village without proper communication, I
tell you - you can be chased away.” (Religious
leader, FGD6)
Potential community distrust of HIS was seen by all
stakeholder groups as likely to limit the recruitment of
HIS volunteers.
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“Recruiting participants could be a problem in most
communities due to misunderstanding the informa-
tion and not completely trusting the people who
conduct the research.” (Religious leader, FGD6)
In addition, frontline researchers saw the potential for
rumour as carrying risks for MLW’s reputation and for
the safety of frontline staff in other studies.
“For those who go into the community, like the field
workers, or even the hospital based research staff,
their security and safety […] have you thought about
the safety?” (Frontline research staff, FGD2)
“We are trying hard to build…we have established
community trust, of which we can say that we are
not 100% good; we have got some areas where we
are also lacking, and we are trying hard to maintain
that. So, bringing in HIS […] we might end up ruin-
ing the trust that people have” (Frontline research
staff, FGD2)
Reflections on the overall acceptability of pneumococcal
HIS
As illustrated in the previous sections, many participants
described both benefits and concerns around pneumococ-
cal HIS. To understand overall acceptability, participants
were asked whether they thought HIS research should go
ahead in Malawi. Most felt HIS would be acceptable pro-
vided researchers addressed certain important conditions
(conditions we explain below). Views ranged from high
levels of enthusiasm to more uncertainty but with willing-
ness to consider that HIS could be appropriate.
“Had it been there were these studies done before,
maybe I would have said ‘Yeah it’s OK, this can be
done’. But…I am on the 50-50, yes or no because it’s
the very first time and I am thinking ‘how are they
going to handle issues of safety?’” (REC member, KII)
“As a Malawian citizen I believe this research is
really necessary, because people in our country are
struggling […] in our hospitals, doctors try to save
lives but lives are being lost. Now researchers have
suggested new methods that can be tried to save
lives.” (CAG member, FGD3-Fup)
Positive overall views of HIS were often related to the
awareness that many existing medicines were developed
through research with a few people for later public use.
Research was therefore considered a normal and neces-
sary step to improving population health, and so accept-
able even if it may involve risks and burdens for some
individuals.
This same idea of benefit for the greater good was
reflected in discussions explicitly about the ethics of HIS,
and specifically whether HIS research would meet princi-
ples of justice and ensuring a ‘fair offer’ for participants,
with risks and burdens of HIS adequately balanced by the
benefits [27]. Many stakeholders emphasised that some
risk or burden for participants was outweighed by the po-
tential for population health benefit, or discussed the posi-
tive aim behind HIS:
“I feel it is a fair thing … you would get vaccines
developed quickly from a small number of volunteers
which can benefit the population […] so I feel like it
has all those benefits that could outweigh the negative
parts.” (District health management, KII)
Some staff, community leaders and medical students
shared these sentiments.
However, views here varied, and a few stakeholders
were concerned about lack of individual benefit:
“It sounds to me like the benefit is more for the
study than the participants, I can’t see what they
have to benefit, rather than contributing to what-
ever vaccine may be developed in the long term.”
(Senior Clinician, KII)
To promote an adequate balance of benefits and bur-
dens, participants identified a range of conditions and
procedures needed to address concerns around safety
and community reactions and ensure pneumococcal HIS
was ethical and acceptable. These conditions are dis-
cussed below.
Conditions required for the acceptability of
pneumococcal HIS
As reported in the previous section, views on the ethical
acceptability of pneumococcal HIS in Malawi were
sophisticated and varied, suggesting that HIS might be
acceptable under some conditions but not others. In this
section, we report on stakeholders’ views on what they
considered to be the requirements for ethical and ac-
ceptable pneumococcal HIS.
Voluntary and informed consent
All stakeholder groups highlighted voluntary and in-
formed consent as a key condition affecting the accept-
ability of HIS. The priority placed on informed consent
was evident in a discussion about whether a pneumococ-
cal HIS as MARVELS was just and constituted a ‘fair
offer’ for participants. Those stakeholders who viewed
the MARVELS study as ethically acceptable often
emphasised the informed, voluntary consent process as a
basis for this judgement.
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“That is justice because the participant will be
informed; they have got the information and
volunteered. If someone is volunteering, it means there
is justice between you and them.” (Chief, FGD4-Fup)
“A good and thorough information I think will
balance [the benefit and burden], where they will
get the right information, and it has to be exactly
what is going to happen.” (REC member, KII)
As these quotes show, discussion about informed con-
sent emphasised both full understanding and voluntary
decision making. Both aspects would be expected in
most health research, but participants emphasised that
explanations should be particularly clear and open with
HIS, given concerns about community misconceptions,
perceived potential for risk from deliberate infection,
and complexity of information.
“They really need people who have got a strong
understanding of things […] this time we are actually
introducing a foreign body in the human body, right?
So, this thing, it needs somebody to have a clear type
of understanding.” (Frontline Research staff, FGD2)
While the overall emphasis was on transparency, a
small number of participants raised concerns that the
initial description of HIS procedures might cause alarm
if handled badly. One CAG member, for example,
suggested that people should not be told that HIS in-
volved introducing bacteria as people would see this
negatively, although other CAG members disagreed and
emphasised the need for openness. One medical stu-
dent expressed uncertainty about how to balance
openness and avoiding concern, given that the idea of
being infected may cause fear:
“We want the person to be informed, but then I
think we need to be careful with these details
because we may end up scaring people. […] I don’t
know how we can put it because we need to find a
balance between keeping them informed and then
not scaring them away, because it’s really scary.”
(Medical Student, FGD5-Fup)
Involvement of family members in consent was dis-
cussed by many stakeholders, reflecting a concern not to
harm family relationships or household livelihoods and
dominant norms around permission from family mem-
bers, particularly for women. Again, enabling discussion
with family is standard practice for consent in health re-
search, but it was particularly emphasised for MARVELS
because the planned three-day residential stay would
take participants away from home
“People at home are supposed to agree with you so
they are aware where the participant is and what is
happening.” (CAG member, FGD3)
Scope for withdrawal was also an aspect of con-
sent with more specific implications in HIS re-
search. Some medical students and research staff
raised questions about permission to withdraw,
given the need to take antibiotics to clear any infec-
tion and saw this permission as important for vol-
untary consent.
“Maybe the person has volunteered himself, and
then you have injected, you have started medica-
tions, maybe the medications are supposed to run
maybe for the week. And then in the consent we
have a part where it says the person can accept
but at any time can withdraw. What if the medica-
tions haven’t yet finished, but the person maybe
didn’t understand, and says I can’t continue, and
you can’t say “no you have to, you have to!” What
can happen in that situation?” (Frontline Research
staff, FGD1)
Research staff felt safety and the right to withdraw
could be balanced through sufficient explanation and en-
suring participants fully understood planned procedures:
“We will explain to them that we will give you the
bacteria and after that we will see if it can go by
itself, but if it doesn’t and you have fever or
whatever, we will be giving you some medication.
So, if you withdraw, maybe if something can happen
at home, there will be no problem. You can get this
medication if you are not willing to continue.”
(Frontline Research Staff, FGD1-Fup)
The perceived importance of informed and volun-
tary consent had implications for views about accept-
able recruitment approaches. The MARVELS team
was considering using flyers or adverts distributed
through places such as college notice boards or social
media, with phone numbers to contact for further in-
formation. Stakeholders welcomed this approach as
avoiding pressure to take part (perhaps in contrast to
the more typical of face to face recruitment in
communities).
“I support the flyers, they are really good because
when one reads it properly, they will be able to
make a decision to say ‘aaah, I think I should take
part in this research’, because they will read every-
thing for themselves unlike just being told.” (CAG
member, FGD3-Fup)
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“I think it [use of flyers] will be of advantage, be-
cause people will come on their own will, we'll not
coerce them to join the study.” (Frontline Research
staff, FGD2-Fup)
Beyond specific procedures for recruitment and consent,
the value placed on informed and voluntary participation
also affected views on other procedures, particularly inclu-
sion criteria and compensation, as discussed below.
Fair selection of participants
Inclusion and exclusion criteria for HIS participants were
seen as an important consideration for acceptability
among all stakeholder groups. Participants in focus groups
and interviews were asked openly about criteria they saw
as important and for their views on criteria being consid-
ered by the MARVELS team. Views on groups of who
should be either targeted for participation or excluded
reflected concerns related to informed and voluntary par-
ticipation, community interest and misconceptions, equit-
able opportunities for participation between different
population groups, burden on livelihoods or other activ-
ities, and ensuring research value and validity through a
sample population considered relevant and unbiased -
principles that were sometimes in tension.
The health status of HIS participants was raised by all
stakeholder groups as an important consideration. Stake-
holders recommended excluding people with long-term
or acute conditions that might increase vulnerability to
pneumococcal infection, as well as people allergic to the
antibiotics used to clear the infection and those with
other contraindications. They urged thorough screening,
particularly because potential volunteers may be un-
aware of underlying conditions.
“I would be worried about […] people who have
diseases that would lead them to be vulnerable to any
sort of infection. So, people who have chronic
comorbidities like a heart failure patient or somebody
with chronic renal dysfunction.” (Senior clinician, KII)
“I think this research is suitable for someone who has
been screened, someone who has no health problem,
so that when they are infected, their body will easily
fight the infection.” (CAG member, FGD3)
Views on inclusion of people with HIV were mixed,
with concerns for safety but also for equity and rele-
vance of the findings for a high-risk group. Many felt
people with HIV should be excluded due to vulnerability
to infections. However, some also discussed the need to
ensure any resulting vaccine to be suitable for people
with HIV, given their susceptibility to pneumococcal
infection.
“This vaccine is not only going to those who are
HIV negative, […], so don’t you think that we
will also need to study those who are on ART, if
we give them this vaccine, how is it going to
work? Or like are we not leaving them aside?
(Frontline research staff, FGD1)
As one way to balance these concerns for safety, equity
and relevance, senior clinicians felt people with HIV
might potentially be included if they were virally sup-
pressed, though they felt more information was needed
to make this decision:
“In my view, I don’t necessarily see that as a severe
contraindication, if we have evidence that they have
an undetectable viral load, but I don’t know” (Senior
Clinician, KII)
Beyond criteria around health, stakeholders dis-
cussed three criteria under consideration by the
MARVELS team: restricting participation to medical
students, people fluent in English, and those with
higher levels of education. The MARVELS team pro-
posed these criteria to ensure potential participants
could fully understand study information and to fa-
cilitate discussion with MARVELS clinicians, some of
whom are British and without fluent Chichewa.
Stakeholders saw potential benefits of these criteria
for informed consent, and some supported restricting
participation to these groups.
“I think the idea of involving medical students will
be better because considering the…. understanding
the concept, it’s easier for us (medical students), but
for people out there it’s not going to be easy.”
(Medical student, FGD5)
However, many stakeholders thought focusing only on
these groups would be inequitable and deny opportun-
ities for participation to others.
“If we say that participants should be determined
by a certain level of education, we are being
biased. Someone may be able to understand but
not be educated to the standards you want.”
(Chief, FGD4)
A further concern was that restricting participation
might affect community views of the relevance of the re-
search if participation was later expanded, or of the
resulting vaccine.
“If you focus only on educated people, there will be
a lot of questions around equity, whether the
Kapumba et al. BMC Medical Ethics           (2020) 21:14 Page 8 of 15
findings can be trusted, safety of volunteers and
being unsure if the research has even started. It
would be better to recruit some educated and some
uneducated people, so the results represent both
sides.” (CAG member, FGD3-Fup)
To address these concerns, some suggested broad-
ening the sample, and involving Malawian clinicians
in the research team or using translators to enable
communication, as they had seen with other studies
or in hospitals where translators assist English-
speaking clinicians.
Adequate medical care
Medical support to ensure participant safety was viewed
as critical for the acceptability of pneumococcal HIS re-
search in Malawi. Key discussions related to the
provision of adequate healthcare, the planned residential
stay, and other measures designed to ensure safety.
Healthcare facilities Stakeholders emphasised the need
for high-quality healthcare facilities and procedures of
the same standard as those in HIC:
“The standard should be better than the ones used
in Liverpool, because in Liverpool obviously they
have more resources for controlling […] let’s say
things get out of hand, as compared to here, we do
not have a lot of resources that can help us to
control. So, monitoring will have to be of the best
standard.” (Medical student, FGD5)
Participants also emphasised the importance of ad-
equate laboratory facilities and experienced staff with
the skills to support volunteers if they develop an infec-
tion. These technical and ‘backroom’ aspects were men-
tioned particularly by stakeholders from medical and
research settings.
“It’s fine to do it but after we have made sure that
everything is in place, we have a laboratory that is
of high quality, the inoculum will be kept there safe,
we have the expertise.” (Senior clinician, KII)
As well as staff with experience in HIS and
pneumococcus, some participants mentioned the
need to involve local staff for both, building research
capacity and because of their existing trust by
participants.
“You need to include local clinicians. Clinicians
who are well known by people and who also
should develop skills in carrying out that type of
study.” (REC member, KII)
Residential stay As previously described, the MARVELS
team plans a three-night residential stay for participants
following inoculation at an accommodation that is lo-
cated in close proximity to one of Blantyre’s private hos-
pitals. This residential stay was generally welcomed by
stakeholders as important for safety, allowing easy access
to medical care and the research team.
“It’s good you thought of arranging the residential
stay to protect participants, because they will be close
to Mwaiwathu hospital (private hospital in Blantyre).
It will be safe for participants.” (Chief, FGD4)
However, while the residential stay was welcomed for
medical support, there were some concerns about the
impacts on household members left behind, and com-
munity participants in particular worried about the im-
pact on livelihoods if the breadwinner is away from
home. Some participants also mentioned that people
may dislike being away from home or feel trapped in the
hostel.
Views on an alternative non-residential option were
mixed. Some felt this could not be considered for initial
HIS studies, but others felt a non-residential option
should be allowed, particularly if volunteers live close to
the hospital or have good transport and communication
access in case of adverse events.
“I think if the person stays in the city or has a car, it
won’t be difficult; if they face any problem, they can
rush to the hospital straight away.” (CAG member,
FGD3-Fup)
Additional safety measures Several additional measures
were proposed by the MARVELS team as part of a pack-
age of medical support, largely following procedures
used with pneumococcus HIS in the UK. This included
providing an emergency package of antibiotics and a
thermometer so that participants could take their
temperature daily to monitor reactions to inoculation
and treat themselves in case they could not access med-
ical care in an emergency. Stakeholders generally saw
this package as useful. However, many raised concerns
about limited understanding of thermometer use and
improper use of antibiotics, particularly among volun-
teers with less education or no medical training.
“If it’s the medical students then it’s OK, but if it’s
not, it’s better they just come to be checked […] if
he is not that well educated, if they just feel a fever,
you are not sure that they will actually take the
drugs as they have been advised…some may even
overdose.” (Frontline Research staff, FGD2-Fup)
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“Our friends in the UK are more advanced; they
know how to use a thermometer, whereas someone
from Malawi doesn’t know how it’s properly used.”
(CAG member, FGD3-Fup)
To address this potential for misunderstanding, stake-
holders suggested clear explanations for HIS volunteers
about how and when to take the drugs, or follow-up visits
at home by the research team to monitor antibiotic use.
Other medical support procedures proposed by the
MARVELS team were generally seen as adequate, includ-
ing 24-h access to a study doctor, availability of a research
team member at the residential hostel, a sequence of mon-
itoring visits to check for symptoms, and daily phone con-
tact by the study doctor. With these procedures in place,
most stakeholders felt reassured about safety.
“There is protection. If they see that a participant’s
health has changed, they will rush them to the hos-
pital, showing that there is help. So, we cannot have
any concerns.” (Chief, FGD4)
Compensation and reimbursement
Compensation of volunteers participating in HIS re-
search was identified by all stakeholder groups as im-
portant for acceptability. Within this, many participants
mentioned reimbursing HIS volunteers for transport
costs (for example, to attend monitoring check-ups at
the hospital), and compensation for time away from
income-generating activity. The latter was particularly
important given the three-day residential stay.
“If he earns 2,000 a day [about £2], then that 2,000,
you need to cover it for those days he participates
in your study” (CAG member, FGD3-Fup)
Stakeholders also discussed compensation for risk.
Some felt compensation for HIS participation would be
higher than for other studies as they perceived HIS as
higher risk:
“For the HIS I am sure we would go for a bit higher
looking at the risks associated.” (REC member, KII)
However, others thought compensation should be
similar to other studies, to avoid reducing recruitment
for other studies or creating undue inducement. Con-
cerns about undue inducement were mentioned by sev-
eral stakeholders and considered a particular risk for less
educated or lower-income groups.
“Here in Malawi, we have a lot of people who
are poor, and poverty might be one reason they
join the study, because of the incentives. They
completely don’t understand the study, but because
they want to make ends meet, they’ll just join.”
(Medical student, FGD5)
Views on the amount of reimbursement and compen-
sation varied widely, with suggested figures ranging from
15,000 [about £15] to 300,000 [about £300] for the 3-day
residential stay, plus additional amounts covering trans-
port for hospital visits. Often stakeholders found it hard
to indicate specific amounts and suggested that compen-
sation be determined by researchers based on standard
practice and guidance.
“I feel like every organisation has its way of providing
incentives and it would also be best to look [at] what
do other organisations recommend on the type
of incentives you can give to someone when you
are involving his life and his health.” (Medical
Student, FGD5)
In relation to how reimbursement and compensation
should be given to volunteers, most stakeholders felt it
should be spaced throughout the study, to cover costs as
they arise, and so reduce burden, and to support retention.
As well as compensation for time and burden, stake-
holders indicated the importance of insurance and com-
pensation in the event of severe adverse events.
“As long as there is an agreement that you will take
care of everything if the volunteers fall sick or die
while participating, then we don’t have concerns.”
(Chief, FGD4-Fup)
Regulation
Stakeholders emphasised the need for careful review and
approval of any HIS in Malawi by research ethics com-
mittees (RECs) and other regulatory bodies such as
pharmacy, medicine, and poisons body (PMPB), to pro-
tect the safety of participants:
“They have to give approvals to show that they have
met the standards, and they are not bringing any kind
of harm to these people.” (Medical student, FGD-Fup)
However, participants involved in medical care and re-
search expressed concerns over the lack of standard
regulatory guidelines on HIS to guide the local regula-
tory bodies.
“But also making sure that there are clear guidelines
from the regulators […] because this will be the
first study. I don’t know if our regulators have got
guidelines to conduct this type of research” (Senior
Clinician, KII)
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Community engagement
Community engagement was considered by all stake-
holders as a key component if HIS research is to be ac-
cepted in Malawi. As previously described, the potential
for negative community reactions and distrust in HIS
was a key concern for all stakeholder groups. However,
many emphasised that adequate community engagement
to promote understanding could overcome this concern:
“There should be enough awareness raising among
everyone, so they know the importance of HIS. This
will ensure they understand what will happen in the
study and they will be able to explain to other
people who might be creating stories about it.”
(Religious leader, FGD6)
Comments on community engagement focused on
raising awareness, sharing information about HIS, and
providing an opportunity for people to ask questions.
However, a few stakeholders also mentioned more two-
way engagement with community input to HIS design,
particularly seeking feedback from participants once HIS
research begins.
On approaches for community engagement, partici-
pants suggested a range of channels, including working
with chiefs, community opinion leaders, and the media
to reach potential participants and wider communities.
“I think the channels to use are chiefs, CAG
members, or churches. […] even radio and TV
stations so that many people hear the information.”
(CAG member, FGD3-Fup)
Community stakeholders also emphasised the presence
of a HIS scientist during any community engagement activ-
ity to respond to any questions and give clear information.
“You may face challenges with lots of questions. As
we (chiefs) are holding meetings, you [the scientist]
should be present to explain things to people
clearly.” (Chief, FGD)
The acceptability of other types of HIS beyond
pneumococcal studies
The views above relate to HIS focused on pneumococcal
carriage. Participants were also asked for views on the ac-
ceptability of HIS for other diseases that require different
procedures. Stakeholders had mixed views about the ac-
ceptability of other types of HIS, particularly HIS, such as
malaria or typhoid, that are more likely to cause symp-
toms or require a longer residential stay or quarantine.
The higher likelihood of developing symptoms was
seen by some stakeholders as a concern for safety, al-
though others felt it could be justified by the high
burden of the disease considered (for example, malaria)
and acceptable with adequate medical support, including
close monitoring.
“I think people will be more scared of the higher
risks. But still more it’s worth doing it because like I
said about malaria, there are a lot of people who are
affected by malaria” (Medical student, FGD-Fup)
A longer residential stay or quarantine was considered
positive for safety (including protecting participants and
stopping the spread of infection to the public), but
stakeholders mentioned potential negative impacts on
family and livelihoods and concerns around participant
comfort. Reasonable compensation and clear informa-
tion on the procedures were identified as preconditions
for acceptability.
“Let’s say the man is a breadwinner at home – staying
for 20 days is difficult. […]. In that situation, you will
provide not only transport but consider an
amount to match the income he is missing.”
(CAG member, FGD-Fup)
Several stakeholders suggested starting with pneumo-
coccus and then gradually expanding to other, potentially
more challenging, diseases if initial HIS go smoothly and
produce useful findings.
“Because this is just the first HIS research start-
ing in Malawi, it might be a bit risky in general;
but I think as we go along we will see that
maybe it’s going on well with the experience and
there will be no problems with other types.”
(Frontline research staff, FGD-Fup).
Discussion
Our findings suggest that pneumococcal HIS research
could be acceptable in Malawi, provided certain condi-
tions are met. Many stakeholders saw HIS as potentially
beneficial for population health, but they also had con-
cerns, particularly related to safety and community reac-
tions. Acceptability depended on approaches to aspects
such as inclusion criteria, compensation, medical sup-
port, and community engagement. Many of the condi-
tions highlighted by stakeholders reflect those in
existing guidance on HIS, and in ethical guidance on
biomedical research in general in LMIC. In this sec-
tion, we compare our findings to existing guidance
and draw out implications.
Many of the conditions for the ethical conduct of HIS
proposed in existing guidance were discussed by stake-
holders in Malawi. For example, stakeholders mentioned
achieving an adequate level of informed consent, fair
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selection of volunteers, appropriate compensation, safety
measures to minimise potential harms and discomforts,
and robust community engagement [2, 4, 28, 29]. Stake-
holder views helped to indicate what these principles
might mean in the Malawian context.
Informed and voluntary consent was seen by many
participants as a central condition, and critical for en-
suring HIS is ethical and a fair offer. The idea of pro-
viding information through flyers or websites (rather
than face to face) was considered potentially valuable
for supporting voluntary decisions but needed to be
accompanied by opportunities for an in-person dis-
cussion. This approach is in line with suggestions that
recruitment for HIS participants should involve the
distribution of advertisements on flyers and posters,
followed by a comprehensive information package and
information meeting [29]. Using flyers as a first step
in the information chain could potentially miss people
who are illiterate but who would be interested in tak-
ing part. Experience with other research in Malawi
suggests that information about opportunities to par-
ticipate in HIS would spread by word of mouth, so it
may reach people unable to read flyers [20]. Inclusive
forms of communication that reach all potential par-
ticipants should be considered for future HIS, for
example, ensuring providing engagement material in
local languages.
Importantly for study design, ensuring informed
and voluntary consent depends on more than the re-
cruitment process, and stakeholders discussed the
impacts on the consent of inclusion criteria and
compensation.
In relation to inclusion criteria, stakeholder views
reflected principles and potential tensions indicated in
existing guidance. In particular, existing guidance notes
the need to promote safety by potentially limiting par-
ticipation to those with English or more education, but
also the potential inequity of these exclusions [5, 30].
The compromise suggested by some participants in our
research was to start with a narrower group of partici-
pants and potentially broaden inclusion criteria as ex-
perience with HIS grows. However, views varied, with
some stakeholders prioritising safety and others equity
(primarily community members, who might be ex-
cluded). Another concern highlighted by our participants
in relation to limiting HIS to more educated groups was
the need to focus on groups most affected by the target
disease. This may partly reflect limited explanation dur-
ing FGDs about the use of follow up on trials after HIS
that test vaccines in a broader population. Further
public engagement that explains the sequencing and
discussed the extent to which relevant results can be
achieved in non-target groups would help to consider
and assess this concern.
A related angle not discussed in the HIS literature but
of concern for some stakeholders in Malawi was the
need for communities to perceive the study as relevant
to them, not just for the results to be medically applic-
able; limiting inclusion was seen as potentially limiting
wider community interest and support, and potentially
future vaccine uptake.
The restriction to healthy adults proposed in exist-
ing guidance [4, 29] was widely supported by stake-
holders in Malawi, along with the need for careful
screening [2, 31]. The need for screening held a
particular significance in the Malawian context
where HIV rates are high, and status is often un-
known [32]. Views on inclusion of people with HIV
reflected the same tensions between safety, equity,
and relevance seen with restrictions based on educa-
tion and medical training: stakeholders recognised
the need for people with HIV to have access to a
vaccine that works for them, but also had concerns
about adequate immunity.
Views on compensation also reflected some of the
principles and tensions in the literature [2, 7, 9, 33].
Some stakeholders felt HIS volunteers should receive
higher amounts, in line with suggestions in some guid-
ance [34]. However, other stakeholders were concerned
about undue influence, a concern widely shared in litera-
ture [2, 13, 28] and of particular significance in LMIC
contexts where poverty may increase the value of study
compensation [10]. Existing research in Kenya shows
compensation can be a key driver of participation [10],
but other studies in Kenya suggest compensation did
not involve undue influence, and also did not set a pre-
cedent – another concern for some stakeholders in
Malawi [8]. While many stakeholders suggested amounts
for financial remuneration, some talked about access to
health care as a potential form of compensation, reflect-
ing the costs of accessing high quality (private sector)
health care in Malawi.
Stakeholder discussions of compensation often highlighted
the impact of participation on livelihoods and house-
holds, reflecting a context where many people have
minimal if any savings, no formal employment, and rely
on daily earnings through small-trading or other self-
employment. In this context, even a short break in
work can have significant effects on household liveli-
hoods. Restricting participation to more educated
groups may mean participants are more likely to be in
formal employment, such that this is less of a concern.
However, impacts on household well-being should be
discussed with potential participants during recruit-
ment and assessed through future study monitoring.
Many stakeholders suggested that compensation levels
should be decided by the research community. In line
with this, compensation levels for MARVELS will be
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discussed with the REC and based on recent guidelines
for Malawi [35, 36],1 but ongoing monitoring to under-
stand participant motivation will help to assess whether
amounts and forms of compensation are appropriate.
The need for medical support to minimise risks and
protect participants from harm was widely discussed,
reflecting concern for safety. Availability of adequate
medical facilities in case of harm was a concern for par-
ticipants, given the constrained resources of the health
sector in Malawi and consequent impacts on access to
timely and quality care. Participants were generally reas-
sured by plans for regular monitoring of participant
health, continuous access to clinicians, and the residen-
tial stay to facilitate quick hospital access; an approach
used effectively for HIS in similar contexts [4].
Community engagement is noted in some existing
guidance on HIS but received heavy emphasis from
stakeholders in Malawi. This emphasis on working with
communities is seen in wider guidance on biomedical
research in LMIC [2, 5, 10]. Stakeholders expected crit-
ical public reactions, at least initially, reflecting previous
experience of public unrest and rumours affecting re-
search in this context. Stakeholder views tended to em-
phasise providing explanations and informing the public,
with an instrumental approach of using engagement to
support the effective conduct of research. While sharing
information will be part of public engagement, ongoing
two-way dialogue is needed, as started through this
consultation. This two-way approach is core to guidance
on public engagement in LMICs [37], and needed both
to inform the acceptable design of future HIS and for
the intrinsic value and ethical importance of public
involvement.
A key condition highlighted in existing guidance that
any HIS study must have a strong rationale that can only
be achieved through HIS, received less critical attention
from our participants. A concern for the importance of
research was reflected in numerous comments about the
value of research on pneumonia. However, the need to
use HIS rather than other study models was not ques-
tioned. Many benefits of pneumococcal HIS identified
by stakeholders – such as addressing the high burden of
pneumonia and improving vaccines – are not necessarily
specific to HIS research and might potentially be
achieved through other types of pneumococcal research.
This assumption that HIS was required may have
reflected trust in the expertise of researchers and a lack
of familiarity with different types of vaccine research
among many stakeholders, combined with a descrip-
tion of the rationale for HIS within FGDs and lim-
ited explanation of alternative approaches. Similarly,
it was assumed by almost all participants that HIS
would lead to effective vaccines, with only one se-
nior clinician pointing to potential uncertainty in
study impacts. HIS are one step in a series of studies
needed to bring new vaccines to the market, but
HIS researchers need to maximise the potential for
impact through focusing only on questions with pub-
lic health importance [2, 13], and through engaging
with academic, pharmaceutical and policy stake-
holders to advance translation of findings and pro-
gress along the vaccine development pipeline. This
includes promoting access to any future vaccines
among research communities, in line with broader
ethical obligations regarding post-trial access in
LMICs [38]. Providing this clarity would be in line
with proposals that HIS should have a publicly avail-
able rationale that includes explaining why HIS is
needed rather than alternatives [4].
Our assessment of acceptability is preliminary and
subject to limitations. Participants were unfamiliar
with HIS, and their views will have reflected the in-
formation provided during focus groups and inter-
views. While we sought to ensure information was
adequate and neutral, the provision of alternative in-
formation or research conducted by people independ-
ent of MLW may have resulted in different findings.
In addition, views are at this stage hypothetical, and
perceptions may change when HIS starts. We plan to
continue embedding social science in MARVELS and
future HIS in Malawi to understand participant expe-
riences and views of people who choose not to take
part, to develop our understanding of acceptability,
enable ongoing adaptation of HIS study design to op-
timise acceptability and to inform discussions on eth-
ical approaches to HIS in LMIC settings.
Conclusion
This study was the first investigation of HIS research ac-
ceptability in Malawi. Our findings highlight a range of
concerns and issues to consider in the design of HIS.
Within MLW, the findings informed the decision to
proceed with a pneumococcal HIS feasibility study and
were used in the study design. Summarised findings
were also shared with the Malawi national ethics com-
mittee to support their ethical review of the feasibility
study, and with the MARVELS funder. The findings
highlight the importance of community and stakeholder
engagement, both during initial consideration and design
of HIS, and an ongoing dialogue to build mutual under-
standing and ensure any HIS research is acceptable.
1The National Commission for Science and Technology (NCST)
(2019) provided guidelines on compensation suggest that: “The level of
compensation for research participants be determined on a case-by-
case basis and dependent on the nature and design of a study” [36].
Gordon et al. presented remuneration tables to guide researchers and
regulators on ways to calculate compensation based on study time and
burden [35].
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